A number of immunotoxins have been constructed for antiangiogenic therapy targeting a biomarker of proliferation-dependent pathologies, such as CD105 (endoglin), a TGF-β co-receptor highly expressed in proliferating endothelial cells of the new vasculature in various cancer types [77,78,79,80,81,82]. This evidence concerns the gene ENG and cancer.